Axa S.A. Arcus Biosciences, Inc. Transaction History

Axa S.A.

$32.2 Billion
Q4 2024

A detailed history of Axa S.A. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Axa S.A. holds 231,902 shares of RCUS stock, worth $2.57 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

231,902

Previous 232,266 0.16%

Holding current value

$2.57 Million

Previous $3.55 Million 2.76%

% of portfolio

0.01%

Previous 0.01%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$14.28 - $18.44 $5,197 - $6,712	-364 Reduced 0.16%	231,902 $3.45 Million
Q3 2024 Nov 14, 2024	BUY	$13.69 - $18.01 $903 - $1,188	66 Added 0.03%	232,266 $3.55 Million
Q2 2024 Aug 14, 2024	BUY	$14.59 - $18.48 $1,867 - $2,365	128 Added 0.06%	232,200 $3.54 Million
Q1 2024 May 15, 2024	BUY	$14.83 - $20.18 $934 - $1,271	63 Added 0.03%	232,072 $4.38 Million
Q4 2023 Jul 16, 2024	SELL	$13.43 - $19.63 $846 - $1,236	-63 Reduced 0.03%	232,009 $4.43 Million
Q4 2023 Feb 14, 2024	SELL	$13.43 - $19.63 $75,342 - $110,124	-5,610 Reduced 2.36%	232,009 $4.43 Million
Q3 2023 Nov 14, 2023	BUY	$17.62 - $23.54 $1.58 Million - $2.11 Million	89,450 Added 60.37%	237,619 $4.27 Million
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $34,584 - $44,897	2,038 Added 1.39%	148,169 $3.01 Million
Q1 2023 May 15, 2023	SELL	$15.96 - $23.15 $5,107 - $7,408	-320 Reduced 0.22%	146,131 $2.67 Million
Q4 2022 Feb 14, 2023	SELL	$19.7 - $35.71 $17,434 - $31,603	-885 Reduced 0.6%	146,451 $3.03 Million
Q3 2022 Feb 14, 2023	SELL	$23.23 - $30.07 $1.02 Million - $1.33 Million	-44,074 Reduced 23.03%	147,336 $3.85 Million
Q3 2022 Nov 14, 2022	SELL	$23.23 - $30.07 $1.02 Million - $1.33 Million	-44,074 Reduced 23.03%	147,336 $3.85 Million
Q2 2022 Feb 14, 2023	BUY	$17.23 - $37.73 $980,300 - $2.15 Million	56,895 Added 42.3%	191,410 $4.85 Million
Q2 2022 Aug 15, 2022	BUY	$17.23 - $37.73 $980,300 - $2.15 Million	56,895 Added 42.3%	191,410 $4.85 Million
Q1 2022 Feb 14, 2023	SELL	$28.92 - $41.83 $370,783 - $536,302	-12,821 Reduced 8.7%	134,515 $4.25 Million
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $4.22 Million - $6.52 Million	134,515 New	134,515 $5.44 Million

Others Institutions Holding RCUS

# of Institutions

201

Shares Held

51.2M

Call Options Held

288K

Put Options Held

138K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $799M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.

Account